Market closedNon-fractional
Rani Therapeutics/RANI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
Ticker
RANI
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
San Jose, United States
Employees
140
Website
www.ranitherapeutics.com
RANI Metrics
BasicAdvanced
$99M
Market cap
-
P/E ratio
-$1.29
EPS
0.34
Beta
-
Dividend rate
Price and volume
Market cap
$99M
Beta
0.34
Financial strength
Current ratio
3.095
Quick ratio
2.972
Long term debt to equity
176.14
Total debt to equity
243.619
Interest coverage (TTM)
-12.30%
Management effectiveness
Return on assets (TTM)
-53.03%
Return on equity (TTM)
-172.95%
Valuation
Price to book
13.52
Price to tangible book (TTM)
13.52
Price to free cash flow (TTM)
-1.953
Growth
Earnings per share change (TTM)
-2.28%
3-year earnings per share growth
124.52%
What the Analysts think about RANI
Analyst Ratings
Majority rating from 7 analysts.
RANI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$7.4M
5.71%
Profit margin
0.00%
NaN%
RANI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.36
-$0.27
-$0.29
-
Expected
-$0.40
-$0.37
-$0.31
-$0.20
-$0.27
Surprise
-8.48%
-1.55%
-13.35%
42.62%
-
RANI News
AllArticlesVideos
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
GlobeNewsWire·2 weeks ago
Rani Therapeutics to Participate in May Investor Conferences
GlobeNewsWire·2 months ago
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rani Therapeutics stock?
Rani Therapeutics (RANI) has a market cap of $99M as of July 06, 2024.
What is the P/E ratio for Rani Therapeutics stock?
The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of July 06, 2024.
Does Rani Therapeutics stock pay dividends?
No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Rani Therapeutics dividend payment date?
Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.
What is the beta indicator for Rani Therapeutics?
Rani Therapeutics (RANI) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Rani Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.